Agenus Inc. has announced new clinical data on its combination immunotherapy, botensilimab (BOT) and balstilimab $(BAL)$, at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The results, presented in an oral session, showed that approximately 39% of late-stage, refractory solid tumor patients treated with BOT/BAL were alive at two years. The study included data from 411 patients across more than five cancer types, with 61% having received three or more prior lines of therapy. Additional poster presentations at ESMO 2025 highlighted clinical activity in hard-to-treat cancers, including cervical cancer, MSS metastatic colorectal cancer (mCRC), and non-melanoma skin cancer. The findings support ongoing and future randomized trials, such as the phase 3 BATTMAN trial, and have contributed to the authorization of BOT/BAL for compassionate use in France for patients with refractory MSS mCRC.